Roman Groisberg

Apr 18, 2023 | nature.com | Omar Alhalabi |Roman Groisberg |Andrew Hahn |Aung Naing |Apostolia M. Tsimberidou |Timothy A. Yap | +2 more

AbstractPre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin and paclitaxel. Primary objective was safety and secondary objectives were clinical response and survival. One patient had a dose-limiting toxicity at dose level 4. There were no unanticipated toxicities.